

MetricInstitution has created an ecosystem for innovations and has initiatives for creation and3.2.1transfer of knowledge (patents filed, published, incubation center facilities in the HEI to be considered)


YEARWISE DETAILS

Year	2021-22	2020-21	2019-20	2018-19	2017-18
Number	4	0	0	0	0

Responses: 04

Dr. Shivajirao Kadam College of Pharmacy has well defined research promotion policy, facilities and created an ecosystem through MHRD's Institution's Innovation Council (IIC) to promote innovative research, IPR and Tech transfer. Institute pays prominent attention and puts efforts to inculcate innovative thinking ability in the young students and motivate them to develop research environment.

The institution has placed a strong emphasis on the creation of an ecosystem for knowledge transfer innovation. Through numerous seminars and workshops, a number of reputable professionals interact regularly with students and employees to foster the development of original ideas. The institution provides frequent competitions and activities for the staff and students to discuss and support their creative ideas. The organization constantly motivates the personnel to attend national or worldwide seminars, conferences, workshops, and conventions.







CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

An educational institution should stimulate innovation, research, and provide a supportive environment in addition to teaching and extension activities. The proper management of projects and research initiatives is the fundamental focus of academic and research institutions. Patents, trademarks, copy rights, trade secrets and other types of intellectual property are included in this. Examples include pharmaceutical processes, any new and useful machines, life forms, manufactured goods, pharmaceutical software, copyrighted works, new or improved chemical compounds, pharmaceutical drugs, genetically engineered biological organism and novel applications of existing inventions as,

- 1. To create an awareness about IPR for faculties and students of the Institution.
- 2. To impart training on future endeavors regarding patent filing processes, procedure of IPR, screen projects, make drafts and file patents to the competing authority.
- 3. To conduct workshops, seminars and training course for better understanding of IPR.
- 4. To encourage faculty members and students to go patentable works.
- 5. Frame and keep updated IPR Policy of the Institution.
- 6. Communicate the IPR Policy to the various stakeholders and the Inventors of the Institution, students in general.
- 7. Identify prospective inventions, innovations, service improvement ideas and copy rights.
- 8. Study and recommend inventions etc. for feasibility of converting to patents/Copy Rights.
- 9. Compensate the Inventors with due reward for encouraging inventions.
- 10. To promote technology advancements for improved quality of life and environment protection.






CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

INDEX

Sr. No.	Title of Patent	Name of the author/s	Department of the teacher	Date of Filing / Date of Publication	Patent No. / Application No.	Affiliation	Page Nos.
				2022-23			
1.	Quercetin loaded Eudrajit s100/GMO nanoparticles for antidiabetic use	Dr. Pankaj Jadhav Dr. Sarika Narade/Patil	Pharmaceutics Pharmaceutical chemistry	Date of Filing: 27/07/2022 Date of Publication: 12/08/2022	202221043000 A	Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangali 416305	7
2.	Synthesis of Novel 5 aminosalicylic acid derivatives	Mr. Sagar Jadhav	Pharmaceutical chemistry	Date of Filing: 15/08/2022 Date of Publication: 16/09/2022	202221046325 A	Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara, Gujrat, India- 391760	<u>8 to 9</u>
3.	Synergistic combination of colloidal silver and organic acid for improved stability of hydrogen peroxide	Prof. DD Chougule Dr. Santosh Gejage Dr. Pankaj A. Jadhav Dr. Suhas S. Aawati Dr. Sandip B. Patil Dr. Pravin K Powar Dr. Harshada A. Patil	Pharmacology Pharmaceutical Chemistry Pharmaceutics	Date of Filing: 13/09/2022 Date of Publication: 18/11/2022	202221052149 A	Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangali 416305	<u>10</u>






CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

Sr. No.	Title of Patent	Name of the author/s	Department of the teacher	Date of Filing / Date of Publication	Patent No. / Application No.	Affiliation	Page Nos.
4.	Cosmeceutical products comprising herbal actives for cosmetic or dermatologic use and its manufacturing method	Prof. D.D. Chougule Dr. Santosh Gejage Dr. Pankaj A. Jadhav Dr. Suhas S. Aawati Dr. Harshada A. Patil Mr. Godfrey R. Mathews Mr. Sagar A Jadhav	Pharmacology Pharmaceutical Chemistry Pharmaceutics	Date of Filing: 21/09/2022 Date of Publication : 18/11/2022	202221053893 A	Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangali 416305	<u>11</u>
5.	A novel effect of melia as a darach lin leaf extract on experimental models of inflammatary bowel disease	Ms. Priyadarshani Patil Ms. Laxmi Mane Ms. Sweeti Shewale Ms. Rohini Tate Ms. Mayuri Choundikar Ms. Khushboo Kankalia Ms. Nikita Gurav	Pharmacology Pharmaceutical Chemistry Pharmaceutics	Date of Filing: 21/10/2022 Date of Publication : 28/10/2022	202221060199 A	Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangali 416305	<u>12</u>
6.	Novel polymeric mineral compositions that mimic human kidney stone	Dr. Santosh Gejage	Pharmaceutics	Date of Filing: 22/03/2023 Date of Publication : 14/04/2023	202321020149 A	Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangali 416305	<u>13</u>





CRITERION 3: Research, Innovations and Extension


3.2 – Innovation Ecosystem

Sr. No.	Title of Patent	Name of the author/s	Department of the teacher	Date of Filing / Date of Publication	Patent No. / Application No.	Affiliation	Page Nos.
		2021-22					
7.	Design to scalp scanning device	Dr. Sandeep B. Patil	Pharmacology	3/8/2021	103143 / 347212-001	Biocyte research and development Pvt. Ltd. Sangli	<u>14</u>
8.	Design teeth gap cleanig device	Dr. Sandeep B. Patil	Pharmacology	8/11/2021	106367 / 352790-001	Biocyte research and development Pvt. Ltd. Sangli	<u>15</u>
9.	Thin layer chromatographic chamber	Dr. Sandeep B. Patil	Pharmacology	27/03/2022	137121 / 361317-001	Biocyte research and development Pvt. Ltd. Sangli	<u>16</u>
10.	Combination drug therapy for anticancer	Mr. Rameshwar Ardad	Pharmacognosy	Date of Filing: 27/04/2022 Date of Publication: 13/05/2022	202221024815 A	Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Sangali 416305	<u>17</u>

TRADEMARK

Sr. No.	Particulars	Link	Page Nos.
1	A trademark for HYDRO- KLEAN (LOGO)	Link	18 to 23
2	A trademark for VENTONE (LOGO)	Link	24 to 29





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

INSTITUTION'S INNOVATION COUNCIL

Sr. No.	Particulars	Link	Page No.
1	Institution's Innovation Council (IIC) Certificate	<u>Link</u>	30

INCUBATION CENTRE

Sr. No.	Particulars	Link	Page Nos.
1.	Application for registration of start up to incubation centre	<u>Link</u>	31 to 44
2.	Agreement and Acceptance Letter	<u>Link</u>	45 to 60







3.2 – Innovation Ecosystem

2) PATENT APPL 9) INDEA	ICATION PUBLICATION	(21) Application No.202221043000 A
2) Date of filing of Application :27/07/2022		(43) Publication Date : 12/08/2022
4) Title of the save	ntion : QUERCETIN LOADED	EUDRGIT \$100-GMO NANOPARTICLES FOR ANTIDIABETIC USE
Narostinad Analisation Handland Agelerian No Handland Mathematics Research Definition Research Agelerians Research Agelerians Handland Handland Handland Agelerians	servenetisse, aregelitisse, areas No. No. No. No. No. No. No. No. No. No.	 (1) Revenue of Agadisous () (1) Revenue of Agadisous () (2) Revenue of Agadisous () (3) Revenue of Agadisous () (3) Revenue of Agadisous () (4) Revenue of Agadisous () (4) Revenue of Agadisous () (5) Revenue of Agadisous () (4) Revenue of Agadisous () (5) Revenue of Agadisous () (5) Revenue of Agadisous () (6) Revenue of Agadisous () (7) Revenue of Agadisous
	(d) Using a product consister, surgereit/or are made if this prevented with 1940. Nan commutation in white the a the deconditions of generation is aded Euclogia U100.	Institution with the program garded with the foreign of the program is the program of the program of the program is the program of the pro
100 . 13		
1.1.2		Server and an and a server of the server of

No. of Pages : 24 No. of Claims : 3

The Patent Office Journal No. 32/2022 Dated 12/08/2022





> CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

पेटेंट कार्यालय शासकीय जर्नल


OFFICIAL JOURNAL OF THE PATENT OFFICE

निर्गमन सं. 37/2022	शुक्रवार	दिनांकः 16/09/2022
ISSUE NO. 37/2022	FRIDAY	DATE: 16/09/2022

पेटेंट कार्यालय का एक प्रकाशन PUBLICATION OF THE PATENT OFFICE

The Patent Office Journal No. 37/2022 Dated 16/09/2022







3.2 – Innovation Ecosystem

(12) PATENT APPLICATION PUBLICATION (19) INDIA		(21) Application No.202221046325 A		
(22) Date of filing of A	Application :15/08/2022	(43) Publication Date : 16/09/2022		
(54) Title of the inven	tion : SYNTHESIS OF NOVEL 5-AMING	-SALICYLIC ACID DERIVATIVES		
 (51) International classification (86) International Application No Filing Date (87) International Publication No (61) Patent of Addition to Application Number Filing Date (62) Divisional to Application Number Filing Date 	:C07K0014470000, B01J0035100000, C07K0007080000, C07D0239340000, B01J0031020000 :NA :NA : NA ⁿ :NA ^r :NA :NA :NA :NA	 (71)Name of Applicant : 1)Mr. Sagar Ashok Jadhav Address of Applicant :Ph.D. Scholar, Department of Pharmacy, Sumandeep Vidyapeeth, Deemed to be University, Piparia, Vadodara, Gujarat, India391760		


(57) Abstract :

(3) Australia (1) Assume (2) Australia (2

No. of Pages : 14 No. of Claims : 3

The Patent Office Journal No. 37/2022 Dated 16/09/2022








3.2 – Innovation Ecosystem


(12) PATENT APPLICATION PUBLICATION		(21) Application No.202221052149 A		
(19) INDIA				
(22) Date of filing of	Application :13/09/2022	(43) Publication Date : 18/11/2022		
	ntion : SYNERGISTIC COMBINATION LITY OF HYDROGEN PEROXIDE	OF COLLOIDAL SILVER AND ORGANIC ACIDS FOR		
(31) International classification (84) International Application No Filing Davi (87) International Publication No (81) Proceeder Addision to Application Number (82) Devicement In Application Number Filing Davie	SCR1000150570008, AS L0002200006, AS L0002200000, ASL NA NA NA NA NA NA NA NA	 (T1)Nome of Applicant 1: (T0) Shrughes Kalass College of Plazmacy (Mitros of Applicant Bhagment, AP-Kauthe Digraj Tal-Meng Dies-Sangli Kaushe Digraj Nome of Applicant 1: NA (Table Shrughese) (TAS) (Table Shrughese) (Table Shrughe		



No. of Pages : 16 No. of Claims : 14

The Patent Office Journal No. 46/2022 Dated 18/11/2022







3.2 – Innovation Ecosystem

(12) PATENT APPLICATION PUBLICATION (19) INDIA		(21) Application No.202221053893 A		
(22) Date of filing of	Application :21/09/2022	(43) Publication Date : 18/11/2022		
	ntion : COSMECEUTICAL PRODUCTS USE AND ITS MANUFACTURING ME	COMPRISING HERBAL ACTIVES FOR COSMETIC OR THOD		
 (51) International classification (65) International Application Net Filing Date (7) International Publication Net (7) International Publication Net (81) Public Net Application Net Application Net Application Net State Public Net 	- An Light I Holdman, An Light Holdman An Light Holdman, An Light Holdman, An Light Holdman Holdman Sta Sta Sta Sta Sta Sta	 (?12)Name of Applicant 1 HDF Shraghen Kadase College of Pharmany Marten of Applicant Radiates College of Pharmany Marten of Applicant 1: NA Address of Applicant 1: NA (?20)Name of Environment 1: NA (?20)Name of Applicant 1: NA (?20)Name		

Discissed herewith the newhol of tropically applying home does not arrange gaps used enters and hacogo associate enters in topical latios crean proposition formalistics. The mitically add uncertifically solucitor of appropriate continuation of these importances of termination of the enters of the importance of these importances of these importances of termination of the properties of termination of the importance of termination of the properties of termination of termination of termination of terminations. The investive comparison of termination of termination of termination of termination of termination of terminations of termination of terminations of terminating terminations of terminations of terminations of terminat



No. of Pages : 17 No. of Claims : 9

The Patent Office Journal No. 46/2022 Dated 18/11/2022







3.2 – Innovation Ecosystem

(12) PATENT APPLICATION PUBLICATION		(21) Application No.202221060199 A		
(19) INDIA				
(22) Date of filing of Application :21/10/2022		(43) Publication Date : 28/10/2022		
	ention : A NOVEL EFFECT OF MELIA A AMMATORY BOWEL DISEASE	ZEDARACH LINN LEAF EXTRACT ON EXPERIMENTAL		
 (51) International classification (86) International Application No Filing Date (87) International Publication Number Filing Date (62) Divisional to Application Number Filing Date (52) Abstract : 	:A61P0001000000, C12Q0001280000, A61P0001040000, A61P0013020000, A61B0005024000 :NA :NA :NA :NA :NA :NA :NA	 (71)Name of Applicant : 1)Priyadarshani Paygonda Patil Address of Applicant :Dr. Shivajirao Kadam college of Pharmacy Kasabe Digraj Sangli 416305 MH India		

(57) Abstract :

The present invention relates generally a novel effect of melia azedarach linn leaf extract on experimental models of inflammatory bowel disease. The study was carried out to evaluate the effect on experimental model of IBD in indomethacin induced enterocolitis in rats. The parameters included macroscopic evaluation (scoring of ulcers), estimation of biochemical parameters myeloperoxidase (MPO), lipid peroxides (LPO) and measurement of physical parameters (change in body weight and colon weight). The pretreatment with MAEE at a dose of (300 & 500mg/kg) for seven days before induction of colitis significantly lowered the ulcer score values, retain total body weight and decrease the colon weight. The results observed from myeloperoxidase and lipid peroxidase assays showed significant protection against IBD. The finding of the present study provides the evidence of above plant for its beneficial effects in the patients suffering from Inflammatory Bowel Disease.

No. of Pages : 23 No. of Claims : 4

The Patent Office Journal No. 43/2022 Dated 28/10/2022








3.2 – Innovation Ecosystem

 (12) PATENT APPLICATION PUBLICATION (19) INDIA (22) Date of filing of Application :22/03/2023 		(21) Application No.202321020149 A	
		(43) Publication Date : 14/04/2023	
(54) Title of the invention :	NOVEL POLYMERIC MINERAL	COMPOSITIONS THAT MIMIC HUMAN KIDNEY STONE	
NO (61) Patent of Addition to Application Number Filing Date (62) Divisional to Application	A61B 172200, A61K 380000, A61P 131200, C12N 050710, C12N 097200 NA NA NA NA NA NA	(71)Name of Applicant : 1)Ms. Akshada Guruling Wale Address of Applicant :Premiok Park Sahara 65 Flat No 13, Pimpari Chinchwad Pune Pin- 411033 India. Pimpri Chinchwad 2)Ms. Sapna Rajendra Zine 3)Mr. Shivam Rakesh Shinde 4)Dr. Santosh Maruti Gejage Name of Applicant : NA Address of Applicant : NA (72)Name of Inventor 1 1)Ms. Akshada Guruling Wale Address of Applicant :Premiok Park Sahara 65 Flat No 13, Pimpari Chinchwad Pune Pin- 411033 India. Pimpri Chinchwad	

(57) Abstract

(57) Abstract : Kidney stone disease afflicts 12% of men and 8% of women in the United States, and its rates are increasing. Calcium comprising uroliths are recognized as brushite, whewellite, weddellite, whitlockite and carbonate apatite. Stravite and newbervite are magnesium containing whereas ammoniam acid urate, mono sodium urate monohydrate, uric acid anhydrous, uric acid mono and dihydrate are commonly existing urate stones. This invention relates to designing the novel polymeric mineral compositions that minics human kidney stones. The present invention also relates to the preparation of in-vitro urolithinitie model artificial kidney stones for evaluation of various kidney stone dissolving compositions and us in unitibiotrypsy optimization process. Newer generation polymeric mineral artificial kidney stones that can be useful not only in short wave lithotripsy but also in evaluating herbal as well as allopathic preparations in-vitro for their stone dissolving compositions.



No. of Pages : 14 No. of Claims : 8


The Patent Office Journal No. 15/2023 Dated 14/04/2023





THE REAL PROPERTY AND A DECIMAL OF A DECIMAL	NER	ORIGINAL
Service Servic	LOD .	No. 103143
TOLICATA - TOB	भारत सरकार GOVERNMENT OF I	NDIA
	पेटेंट कार्यालय THE PATENT OFFI	
CERTIFIC	ATE OF REGISTRATIO	
Design No Date Reciprocit Country	03/08/2021	
Certified that the deal and date given above in class DEVICE in the name of UNIVERSITY, KOLHAPUR DEVELOPMENT PYT LTD COLLEGE OF PHARMACY	ga of which a copy is annexed hereto h 24-01 in respect of the application of 1.DR. ABHINANDAN RAVSAHEB 2. DR SANDEEP BALVANT PATI 5. SANGLI 3. DR. SOMNATH DEV KASEGAON 4. DR SHANTIPRAS OLOGY & LEPROSY, BHARATI V DLLEGE & HOSPITAL, SANGLI	DATIL, SANJAY GHODKAN IL, BIO CYTE RESEARCH AND IDAS BHINGE, RAJARAMBAPU
	the provisions of the Designs Act, 2000	and the Designs Rules, 2001.
	age -	
	r General of Patents, Designs a	
"The reciprocity date (if any) which has Copyright in the design will subsist for 1 be extended for a further period of five y This Certificate is not for use in legal pro		
DR. ABHINANDAN RAVSAHEB PATR P3 GAJALATA ARCADE SYKES I SHAHAJI LAW COLLEGE KOLHAPU	TENSION NEAR IGNS 11 8 416001	RADE MARKS ATIONS
Date of Issue 06/10/2021 11:03:24		and the second se
		1. The second se
		the same of the second states





Sign





3.2 – Innovation Ecosystem








3.2 – Innovation Ecosystem

 (12) PATENT APPLICATION PUBLICATION (19) INDIA (22) Date of filing of Application :27/04/2022 		(21) Application No.202221024815 A	
		(43) Publication Date : 13/05/2022	
(54) Title of the inver	ntion : COMBINATION DRUG THERAPY	FOR ANTICANCER	
 (51) International classification (86) International Application No Filing Date (87) International Publication No (61) Patent of Additic to Application Numbe Filing Date (62) Divisional to Application Number Filing Date 	:A61K0031145000, A61K0031496000, A61K0045060000, A61K0031337000, A61K0031498500 :NA :NA :NA :NA :NA :NA :NA :NA	 (71)Name of Applicant : 1)Mr.Rameshwar Madhukar Ardad Address of Applicant Dr. Shivajirao Kadam College of pharmacy Kasabe Digraj.Sangli 416305 MS India. Email idramardad@rediffmail.com Mob no.9503756634. 2)Dr.Shashikant C. Dhawale 3)Dr. Arehalli Sidramappa Manjappa Name of Applicant : NA Address of Applicant : NA Address of Applicant : Dr. Shivajirao Kadam College of pharmacy Kasabe Digraj.Sangli 416305 MS India. Email idramardad@rediffmail.com Mob no.9503756634. "" 2)Dr.Shashikant C. Dhawale 3)Dr. Arehalli Sidramappa Manjappa Name of Inventor : 1)Mr.Rameshwar Madhukar Ardad Address of Applicant : Dr. Shivajirao Kadam College of pharmacy Kasabe Digraj.Sangli 416305 MS India. Email idramardad@rediffmail.com Mob no.9503756634. "" 2)Dr.Shashikant C. Dhawale Address of Applicant : Dr.Shashikant C. Dhawale ,58, Veer Sawarkar Nagar, Wadi Bk, Purna Road Nanded. 431605 MS India. Email id-shashiprathmesh@gmail.com Mob no.9970700030. """ 3)Dr. Arehalli Sidramappa Manjappa Address of Applicant : Department of Pharmaceutics, Tatyasaheb Kore College of Pharmacy, Warananagar -416113 Tal: PangalaDistrict: Kolhapur Mabarashtra Email Id: manju_as82@yaboo.co in Mob No: 9552826871;8956647419 	

(57) Abstract :


(27) Austract : COMBINATION DRUG THERAPY FOR ANTICANCER Abstract The present invention states that the combination therapy useful for treatment of oncological disorders. Further invention relates to Ketoconazole; Disulfiram; and Tadalafil having 1:1:1 molar ratio respectively. Further embodiment of present invention relates to Ketoconazole; Disulfiram: Tadalafil cocktail in combination with Docetaxel and other chemotherapeutic



No. of Pages : 25 No. of Claims : 5

The Patent Office Journal No. 19/2022 Dated 13/05/2022





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

Receipt No.: 3378908 Date: 08/09/2022 Amount: Rs.4500/-Application No: 5602202

FORM TM- A The Trade Marks Act, 1999 Application For Registration Of a Trademark On application to register a trade mark for a specification of goods or services included in one class [section 18(1)]

NATURE OF APPLICATION:	A TRADE MARKS APPLICATION	
APPLICATION FILED AS:	Small Enterprise	
FEE:	4500	
APPLICANT		
Applicant No.	1	
Name	M/S TEERTHANKAR EDUCATION SOCIETY	
Address	01, VENKATESH APARTMENT, SANGLI UNDERGROUND, SOUTH SHIVAJI NAGAR, NEAR IT O, SANGLI MAHARASHTRA- 416416	
Country	India	
Jurisdiction	MUMBAI	
Address for Service	A-96, Brotherhood Apartment, Vikas Puri New Delhi-18	
Mobile No.	9665388581	
Email Address	smgejage01@gmail.com	
Nature of Applicant	Society	
Legal Status	SOCIETY	
APPLICANT'S AGENT (If Any):		
Name	DIKSHA LAL	
Address	A-96, Brotherhood Apartment, Vikas Puri New Delhi-18	
Nature of Agent	Advocate	
Registration No.		
MARK DETAILS		
Category of Mark	DEVICE	
Trade Mark	HYDRO-KLEAN	
Image Description	Logo of HYDRO-KLEAN	







3.2 – Innovation Ecosystem

Trademark Image:	
HYDRO-KLEAN	
IF MARK IN A LANGUAGE OTHER TH	
Language	English
CONDITIONS OR LIMITATIONS TO US	SE THE TRADEMARK, IF ANY
CLASS OF GOODS OR SERVICE	
Class: 1	Description: Chemicals for use in industry science and photography, as well as i agriculture, horticulture and forestry Unprocessed artificial resins, unprocesse plastics; Fire extinguishing and fir prevention compositions; Tempering an soldering preparations; Substances for tanning animal skins and hides; Adhesive for use in industry; Putties and other past fillers; Compost, manures, fertilizers Biological preparations for use in industry and science
STATEMENT AS TO USE OF MARK	Proposed to be used
ANY OTHER IMPORTANT INFORMAT	ION OR STATEMENT
VERIFICATION	I hereby verify that above mentioned fact are true to best of my knowledge an belief.
Date	08-09-2022 09:28 PM

Digitally Signed By DIKSHA LAL

for DIKSHA LAL





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem


and the second	मूक्ष्म, लघ्			erprises	HEALER - A	SINE 1949 by Hand Mark 1941 by Hand Hand Hand Hand Hand Hand Hand Hand
UDYAM REG	IST	RATIO	ON CEF	RTIFIC	ATE	
UDYAM REGISTRATION NUMBER			UDYAM-	MH-29-002	21668	
NAME OF ENTERPRISE		M/S TI	EERTHANKA	R EDUCAT	ION SOCI	ETY
TYPE OF ENTERPRISE *			MICRO (Ba (MICRO I	sed on FY 20 During FY 2019		
MAJOR ACTIVITY			SEI	RVICES		
SOCIAL CATEGORY OF ENTREPRENEUR	GENERAL					
	S.No.			Name of Unit(s	0	
NAME OF UNIT(S)	1	Dr.Shivajira	io Kadam Collej	ge of Pharmacy	, Kasbe Dira	ıj, Sangli
	Flat/I No.	Door/Block	01	Name of Premises/ Building	Venkatesh	Apartment
OFFICAL ADDRESS OF	Village/Town		Sangli	Block	Undergrou	nd
ENTERPRISE	Road	/Street/Lane	South Shivaji Nagar, Near IT	o City	Sangli	
	State		MAHARASHT	RA District	SANGLI,	Pin 416416
	Mobile		9422523034	Email:	skcopharm	deg@gmail.com
DATE OF INCORPORATION / REGISTRATION OF ENTERPRISE DATE OF COMMENCEMENT OF PRODUCTION/BUSINESS				9/02/1998 5/07/2016		
NATIONAL INDUSTRY	SNo.	NIC 2 Digit	NIC 4 Digit	NIC 5 Digit		Activity
CLASSIFICATION CODE(S)	1	20 - Manufactury of chemicals and chemical products		20212 - Manu disinfectants agricultural a use)	(for	Manufacturing
	2	20 - Manufactur of chemicals and chemica products	as a set a set a	(includes man pre- shave, sh after shave pr personal deod	I toileteries sufacture of saving or reparations; lorants and sts; th salts and eparations; ke-up and	Manufacturing










3.2 – Innovation Ecosystem













CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

FORM TM 48

THE TRADE MARKS ACT, 1999

I, PRASHANT SUKUMAR AVADHUT, Authorized Trustee of M/S TEERTHANKAR EDUCATION SOCIETY having its registered office at 01, VENKATESH APARTMENT, SANGLI UNDERGROUND, SOUTH SHIVAJI NAGAR, NEAR IT O, SANGLI, MAHARASHTRA- 416416, do hereby authorize, Ms. Diksha Lal (Advocate) of Lawyer24x having there address at A-96, Brotherhood Apartment, Vikas Puri, New Delhi-110018 as my Advocate/ Attorney/ Agent in connection with filing, maintaining, prosecuting various applications for registration of Trademarks and obtaining registration and renewals, and also to file oppositions and rectification proceedings under the Act. I further authorize the above said Attorney to attend hearings (if any) in relation to the Trade Marks. I also request that all notices, requisitions, and communications relating thereto may be sent to such agents at the above-mentioned address.

I hereby revoke all previous authorization, if any respect of the above proceeding.


All communications relating to this application may be sent to the following address in India.


Diksha Lal (Advocate) A-96, Brotherhood Appt, Vikas Puri, New Delhi-110018 +919599798747

PRASHANT SUKUMAR AVADHUT

Trustee

M/S TEERTHANKAR EDUCATION SOCIETY





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem


Receipt No.: 3378908 Date: 08/09/2022 Amount: Rs.4500/-Application No: 5602203

FORM TM- A

The Trade Marks Act, 1999 Application For Registration Of a Trademark On application to register a trade mark for a specification of goods or services included in one class [section 18(1)]

A TRADE MARKS APPLICATION		
Small Enterprise		
4500		
1		
M/S TEERTHANKAR EDUCATION SOCIETY		
01, VENKATESH APARTMENT, SANG UNDERGROUND, SOUTH SHIVA NAGAR, NEAR IT O, SANGL MAHARASHTRA- 416416		
India		
MUMBAI		
A-96, Brotherhood Apartment, Vikas Puri, New Delhi-18		
9665388581		
smgejage01@gmail.com		
Society		
SOCIETY		
DIKSHA LAL		
A-96, Brotherhood Apartment, Vikas Puri, New Delhi-18		
Advocate		
DEVICE		
VENTONE		
Logo of VENTONE		








3.2 – Innovation Ecosystem

IF MARK IN A LANGUAGE OTHER TH	AN HINDI OR ENGLISH
Language	English
CONDITIONS OR LIMITATIONS TO US	E THE TRADEMARK, IF ANY
CLASS OF GOODS OR SERVICE	
Class: 3	Description: Non-medicated cosmetics and toiletry preparations; Non-medicated dentifrices; Perfumery, essential oils Bleaching preparations and other substances for laundry use; Cleaning polishing, scouring and abrasive preparations
STATEMENT AS TO USE OF MARK	Proposed to be used
ANY OTHER IMPORTANT INFORMATI	ON OR STATEMENT
VERIFICATION	I hereby verify that above mentioned facts are true to best of my knowledge and belief.
Date	08-09-2022 09:29 PM

DIKSHA LAL

for DIKSHA LAL






CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem










3.2 – Innovation Ecosystem







Signed by: Sidharth Patil Reason: NAAC Location: Kasabe Digraj Date: 29-Jun-2023 (04:58 PM)



CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

FORM TM 48

THE TRADE MARKS ACT, 1999

I, PRASHANT SUKUMAR AVADHUT, Authorized Trustee of M/S TEERTHANKAR EDUCATION SOCIETY having its registered office at 01, VENKATESH APARTMENT, SANGLI UNDERGROUND, SOUTH SHIVAJI NAGAR, NEAR IT O, SANGLI, MAHARASHTRA- 416416, do hereby authorize, Ms. Diksha Lal (Advocate) of Lawyer24x having there address at A-96, Brotherhood Apartment, Vikas Puri, New Delhi-110018 as my Advocate/ Attorney/ Agent in connection with filing, maintaining, prosecuting various applications for registration of Trademarks and obtaining registration and renewals, and also to file oppositions and rectification proceedings under the Act. I further authorize the above said Attorney to attend hearings (if any) in relation to the Trade Marks. I also request that all notices, requisitions, and communications relating thereto may be sent to such agents at the above-mentioned address.

I hereby revoke all previous authorization, if any respect of the above proceeding.

All communications relating to this application may be sent to the following address in India.

Diksha Lal (Advocate)

A-96, Brotherhood Appt,


Vikas Puri, New Delhi-110018

+919599798747

PRASHANT SUKUMAR AVADHUT

Trustee M/S TEERTHANKAR EDUCATION SOCIETY





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

This is to certify that

Dr. Shivajirao Kadam College of Pharmacy, Sangli


has established an Institution's Innovation Council () in the campus as per the norms of Innovation Cell, Ministry of Education, Govt. of India during the academic calendar year 2022-23

Certificate No: 13505

Able Code: C-55694 Date: 10-04-2025

INSTITUTION'S INNOVATION COUNCIL CERTIFICATE





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

Annexure -I

SUK Research and Development Foundation (SUKRDF)

A Section 8 Company of Shivaji University, Kolhapur)

B-3, Shivaji University, Kolhapur -416004 CIN: U85300PN2021NPL203774

Tel: +0231-2609440

Application for Registration of Start-ups at Incubator- SUKRDF

Name:- Dr. Santosh Maruti Gejage	Name:- Miss. Nikhat Samir Maindargi
Address:- Plot No-38, Tuljamatanagar Pundi	Address:- 15/664, Kalanagar, Near Maruti
Road Tasgaon Tal- Tasgaon Dist- Sangli 416312	Temple, Ichalkaranji.416115
	PAN card:- FEWPM7603J
PAN card:- AUAPG4489M	Details Adhaar card:-852762318041
Details Adhaar card:- 541888971078	
	Details Email-Id:-
Details Email-Id:- smgejage01@gmail.com	nikhatmaindargi1@gmail.com
Mobile No.:-9665388581	MobileNo.:- 9834421621
Name:- Mr. Nikhil Ananda Gajare	Name:-Miss. Dhanashri Nanaso Mujumale.
Address:- A/P Gotkhindi, Tal:- Walwa, Dist:- Sangli	Address:-Rajaram complex Flat 3,100FT, Lokmanya Chouk, Patrakarnagar, VTC;Sangli.416416
PAN card details:- CHPPG2242E	PAN card details:-GZPPM7732B
	Adhaar card details:-843581247692
Adhaar card details:-556629256753	
	Email-Id:-
Email-Id:-nikhilgajare058@gmail.com	dhanashrimujumale3019@gmail.com

Page1of148





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

. .

1. Brief background/Domain Knowledge of the Promoters:

Nikhat Samir Maindargi

- o Qualification:- B. Pharmacy, Experience:-1 year of Research.
- Nikhil Ananda Gajare
- o Qualification:- B. Pharmacy, Experience:-1 year of research.

Dhanashri Nanaso Mujumale

o Qualification:- B. Pharmacy, Experience:-1 year of research.

Dr. Santosh M. Gejage

- Qualification:- M. Pharmacy & PhD (Tech) in Pharmaceutics/Drug Delivery Systems from Institute of Chemical Technology Mumbal, experience-10 year of Research and Development, Marketing Commercialization and Product Development. Founder Director of Novetra Pharma Pvt Ltd
- Name of the Technology/process/product which is to be incubated at SUKRDF: "Ventone" Hydrogel Based Topical Cream for Management of Varicose Veins
- 3. Brief description about your technology (focusing on the

novelty/Innovation/USP):

- Patented Formulation
- Hydrogel system containing 3 scientifically proven Ingredients
- Acts directly on affected area
- Pricing affordable: 100g-300es
- No staining as per conventional ointment.
- 4. Business plan in brief:

Kindly, fill SUKRDF 8 Plan format

5. What kind of incubation are you looking for: Physical OR Virtual and Why? Virtual, as most of initial proof of concept and scale studies are carried out at Dr. Shivajirao Kadam College of Pharmacy Kasabe Digraj. As the product is in pharmaceutical domain college as required infrastructure facility to support the start up. We require handholding to raise the funds through the incubation center.

 At what stage of development is your technology (ideation/Validation/Prototype/Traction/Scalability):

"Validation stage"

7. Please provide the scope of employment generation through your start-up:

At least 10 People will get jobs through proposed start up. Marketing, Operations and

Page2of148







CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

coordination domain jobs will be created.

 Have you applied for incubation/funding from other agency in India or Abroad, If Yes please provide the relevant details here: NO

 If you are interested to choose a technology/ IP from SUKRDF, please indicate the area/name of the technology.(For more details on the technologies available you may visit our website or come in person to SUKRDF office and discuss with the concerned technical officer)

10. Any other information you would like to provide

Dr. Santosh Gejage

Mr. Nikhil Gajare

Mainda

Ms. Nikhat Maindargi

Austra Ms. Dhanashri Mujumale


(Signature of the Applicant)

•

NOTE: On allotment/ engagement with SUKRDF a separate agreement needs to be signed by the incubate company.

Page3of148





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

SUK Research and Development Foundation

A Section 8 Company of Shivaji University, Kolhapur) B-3, Shivaji University Campus, Kolhapur -416004 CIN: U85300PN2021NPL203774 Tel:+0231-2609440

SUKRDF INCUBATION CENTRE B-PLAN APPLICATION FORM

	YOUR ORGANIZATION
Applicant:	Ms. Nikhat Samir Maindargi Dr. Santosh Maruti Gejage Mr. Nikhil Ananda Gajare Ms. Dhanashri Nanaso Mujumale
Company name:	SKCP Pharma Technologies (Proposed LLP Firm)
Business Registration Number:	
Business Postal Address:	C/O- Dr. Shivajirao Kadam College of Pharmacy Baganwat Kasabe Digraj Tal- Miraj Dist- Sangli Maharashtra
Business Street Address:	
Contact Details (Phone,Fax, E-Mail and Web If Available)	+91 9565388581 Smgejage01@gmail.com
Briefly Describe Your Company:	SKCP Pharma Technologies is technology creating company specifically working on Innovative drug delivery systems in healthcare domain.
	OPPORTUNITY
What type of opportunity is it? (e.g.: wireless technology, online /internet service)	Healthcare
How did the opportunity/concept come about? Please provide us with a brief history.	Varicose vein is most neglected problem in society due to limited available of venoactive drugs. Currently there is only surgical intervention is available for management of varicose veins which is costing at around 1.5 to 2.0 Lakhs per surgery. There is ample opportunity to develop and commercialese the herbal based topical as well as oral tablest for the patients
Describe the product's or service's unique Functionality, technical risks, limitations, etc.	Patented formulation consisting of Purified extracts of Horse chest nut, grape seed and Brahmi. Efficacious and advanced formulation might benefit the patients.
Describe the company's Competitive advantage	Patented and Trademark protected product have competitive advantage in market
	MARKET
What problem are you solving for customers?	 There is only one venoactive compound available in the market i.e Calcium Dibasilate (dobimust).

Page4of148








3.2 – Innovation Ecosystem

	 Lack of allopathic medicine in the market. There are less scientifically proven ingredient available. The study of aescin has been done from 40 years. Reparil gel is available in the market but in Italy Market not in India. There is need to incorporate scientifically proven ingredient for development of topical lotion for management of Varicose vein. 	
How are you going to solve it?	 As there is only calcium dibasilate is available in the market, So we have prepared the hydrogel system for treatment of Varicose vein. This topical hydrogel can improve blood flow and muscle tone might reduced the risk of developing varicose veins. This are scientifically proven ingredients. As this is topical hydrogel patients are more convenient to use and apply. The cost of surgery is very high so to reduce these cost and pain we have prepared this hydrogel. So that patient can afford this cost and treatment. 	
Have you undertaken any Market research?	Yes	

Page5of148







3.2 – Innovation Ecosystem

	If yes please tick what there search covered: Competing Products similar Products Similar Business Models Size Of Market (Value) Demographic Other-please describe Please also describe what research was undertaken and use the results of there search to inform you answers to subsequent marketing questions:
What market segment are you Going to target?	Primary and secondary patients of Varicose veins
What is the size and grow threat of this market?	Please detail market assumptions with factual information backing assumptions as appropriate. Size: S00 Cr Growth rate: 10%
How are predicted industry trends going to affect the business?	Herbal and neutraceutical products as well as Allopathic preparations
What problem are you solving For customers?	There is only one venoactive compound available in the market Le Calcium Dibasilate (dobimust). Lack of allopathic medicine in the market. There are less scientifically proven ingredient available. There such a scientifically proven ingredient available. The study of aescin has been done from 40 years. Reparil gel is available in the market but in Italy Market not in India. There is need to incorporate scientifically proven ingredient for development of topical lotion for management of Varicose vein.
What are your market entry Strategies?	Topical Gel will be launched in initial launching phase to entry in the market followed by oral nutraceutical tablets. After 2 years of presence in market, improved versions of products. Newer combination of herbal actives will be launched to make lead the market,
How will you maintain and Develop your market?	Offline and online marketing through Medical representatives. OTC advertisements through newspapers for creating awareness about the product followed by capturing the market
What is your Marketing Mix	Offline and online marketing
How the customer be found and retained?	 OTC advertisements through newspapers for creating awareness about the product followed by capturing the market. Visiting Surgeons to aware the product
Does the market appear viable/accessible? Is it proven?	Viable Yes it is proven
market entry, can these be overcome and how?	Barriers are:- Licence to Manufacture the product under D&C Act 1940 Either ayurvedic or cosmetic license required Human clinical trails _May be required if launching under allopathic idomain. If interested to sell in drug license. Regulatory approval from FDA

Page6of148






CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

Are there existing marketing and distribution channels?	No. Need to be cre	ated
What is your unique selling Proposition (USP)?	 Ayurvedic product Patented Formulation Hydrogel system Acts directly on affected area Pricing affordable: 100g-300rs No staining as per conventional ointment. 	
How long will it take to get the product/service to market?		6 months
Is this product or service the First in the market?		Yes
What is the product or service Lifecycle?		Mini 2 years
How could advancing Technology changes the market?		Pharmaceutical Market are driven by doctors' prescriptions. Sometime through strong advertisements

	COMPETITORS
Who else is in your planned market? How are customers currently solving the problem you propose to Address?	Surgery Stocking
Why are customers going to Buy from you?	 As this is topical hydrogel patients are more convenient to use and apply. The cost of surgery is very high so to reduce these cost and pain we have prepared this hydrogel. So that patient can afford this cost and treatment. scientifically proven ingredients.
What are the barriers to Entry for competitors?	Patent Protection Brand Name protection

Page7of148





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

.

	INTELLECTUALPROPERTY
is the technology protectable? (yes / no)if yes "how is this Intellectual property currently protected?"	Yes Patent and trademark
Do you enquire intellectual property protection? Yes/no if yes: • What type of protection? • What will be the IP protection cost?	No
What kind of intellectual property do you own? Please provide detailed information (patent, Copyright, design, trade secret)	Patent No:- TM Application No:-5602203 Date of Application:-08/09/2022 TM for:- Ventone TM Category:- Trademark
Does business success depend on any external Intellectual property?	NO
 Ves/No if yes: Who owns the IP? Does The Business have licenses or agreements in place? Yes/no if yes, Please describe: 	Patent and Tradmark Owned by Dr. Shivajirao Kadam College of Pharmacy Kasabe Digraj. License will be made to commercialese the technology
s there a sustainable technical or proprietary competitive advantage for he product or service? /es/no f yes, please describe:	Yes. Patent contains formulation in which purified extracts were disclosed which will add superior advantage.
lave you registered domain names? f yes, what are they and in which ountries?	No

Page8of148






CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

	TECHNOLOGY
What type of technology are you using? Please describe the technology you are using.	Hydrogel based Herbal extracts for Topical Application.
Describe how this technology applies to your target market	Conventional products are in either cream/ointment forms which consists of raw extracts where the efficacy of formulations are poor due to extraneous matters. In case of the patented formulation it consist o advanced forms of herbal actives and improved drug delivery systems.
Are software design and technology certification procedures in place? Yes/no If yes, please describe the Procedures and their application:	NO
Are product development procedures in place? Yes/no If yes, please describe:	Yes Record are maintained
Are testing procedures in place? Yes/no If yes, please describe:	Yes Testing Procedure as per In-House specifications for final formulation.
Has the technology proven to be feasible? Yes/no If yes, please describe:	Yes Need by patients and doctors
Please identify and describe competing technologies (current, and anticipated future)	Currently no such technology is available in india

Page9of148








3.2 – Innovation Ecosystem

	Accomplishments to date
At what stage of development is your business?	Please choose one of the following: Under taking pre-business research and development, or testing an idea; Working on a prototype; product or service in
How long have you/your Team been working on the concept?	From January 2022
Do you have any current customers? Yes/no If yes, please describe: • How many? • Are they paying customers? • How many are repeat customers?	No
What recognition have you achieved to date? Please list:	

Page10of148








3.2 – Innovation Ecosystem

Do you have any strategic alliances? If yes, who are they and what type of relationship do you have (i.e. Equity transfer, license Agreement)? BUSINESS MODEL Revenue from selling products How are you going to make money? . For example, advertising, transactions . Revenue from Licensing the fees, fee for service , subscription based, technology etc. list all your revenue Revenue from licensing the brand Streams and their relative importance. name-Ventone Through doctors prescription Patients who are suffering from Varicose veins Who is going to pay you for the service/product? For example, the end user uses the service for free and advertisers are the ones who Pay you NO Have these assumptions been tested?(ves/no) If yes, please provide a detailed description, examples And references from users: Are financial projections available?(yes/ no) If yes, please attach. If no, consult SUKRDF incubation manager to develop these 2 Years What is your anticipated time To break-even? COMPANY BOARD Board of Directors: - Dr. Santosh M. Is an operation board in place(yes/no) . Gejage Board of Advisors: - Dr. Sandip Patil & If yes, please list your board include . gualifications and experience: Prof. D D Chougule Own industry and experience of Industrial . Knowledge. Yes Does the company board meet regularly?(yes /no) If yes:

Page11of148





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

 List frequency of meetings What reports are provided to the board? (provide examples e.g.: status reports, financial statements(e.g. income Statement, balance sheet) 	
	MANAGEMENT TEAM
Please list your management team	1.Nikhat Samir Maindargi 2. Nikhil Ananda Gajare 3. Dhanashri Nanaso Mujumale
Have you managed businesses previously?(yes/no) If yes, please provide details(business name, brief history)	Yes Dr. Santosh Gejage is Director of Novetra Pharma pvt Ltd from last 5 years.
Do you have advisers to your current business? (yes/no) If yes, please describe and provide details of experience	 Board of Advisors:- Dr. Santosh Gejage & Prof. D D Chougule Own industry and experience of Industrial Knowledge.
	TECHNICAL TEAM
Please list your technical team Include qualifications and experience	1.Nikhat Samir Maindargi 1 Year Experience 2. Nikhil Ananda Gajare 1 Year Experience 3. Dhanashri Nanaso Mujumale 1 Year Experience 4. Dr. Santosh Gejage 12 Years of Experince
	RISK ANALYSIS
Have you under taken a risk analysis process? (yes / no)if yes, please list (e.g.: managerial, technical, financial, market, product, Development, sovereign risk) • What are your identified risks? • What strategies have been identified to manage risks?	NO
Please provide a template for Risk matrix–issue–ranking(high/ medium/low)	
What do You Require to Get	INVESTMENT PROPOSAL
What do You Require to Get You to the next level? For example, legal services, Accounting services, etc. please be specific.	Capex to start operations around 25 Lakhs Legal services to incorporate company R&D Services to have clinical studies on human subjects

Page12of148







3.2 – Innovation Ecosystem

	Funding to launch and market the product.
How much capital has been invested in your company to date? Include eco pyofsha reregister if available	100000/-
How was this capital used? e.g.: wages & salaries, insurance, product development, marketing, infrastructure (computers, tools, etc), rent and other overheads, vehicles. Please attach financial statements And a balance sheet if you have them.	product development IP Protection Scale up studies Characterization of Product
Do you have a plan to raise Further capital?	Yes
	Equity dilution Family and friends Other -Loan from Banks/Govt funding suppor
	If yes: • How much investment is
	Required? 2500000/- • When do you require any
	Additional funding? For commercialization stage
	Example, at what stage does
	Your planned business
	Development strategy
	Require funding? Do you prefer a single
	Investor/combination of
	Investors?" Yes

Page13of148





Teerthankar Education Society's Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj

CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

How many rounds of Investment are planned?"(please describe) Not Yet planned How will investment funds be utilized? NA What is your average cash Utilization rate per month? EXITSTRATEGIES YES/NO Do you have an exit strategy for the **IFYESPLEASESELECTONE:TRADESAL** business? E IPO REDEMPTION DON'TKNOW When do you anticipate NA Investors would exit?

Alminda

Ms. Nikhat Samir Maindargi

Mr. Nikhil Ananda Gajare

Ciju .

N 2 Dr. Santos ruti Gejage

Ms. Dhanashri Nanaso Mujumale

Name and Signature of Incubatee

SKCP Pharma Technologies (Proposed LLP Firm)





CRITERION 3: Research, Innovations and Extension 3.2 - Innovation Ecosystem

SHIVAJI UNIVERSITY, KOLHAPUR Shivaji University Centre for Innovation, Incubation and Linkages (SCIIL) &

SUK Research and Development Foundation (SUKRDF) (4 Souther # Compare Registered with Motiony of Compares Affeirs, Gol) minufficustibilized acide / addition/Minufe.ac.de / 0021 (Senser)



Date: 13/02/2023

SUKRDF/

To, Smt. Nikhat Maindargi Smt. Nikhat Mainda 15/664, kalanagar, Near Maruti Temple, Ichalkaranji, Kolhapur, 416115

Subject :

Reference:

Startup incubation at Incubation Centre of Shivaji University, Kolhapur. Your startup idea serutinized on 20 December, 2022 for startup incubation at Incubation Centre of Shivaji University, Kolhapur.
 Your consent by email regarding acceptance of the offer for startup Incubation at Incubation Centre of Shivaji University, Kolhapur dated 11 February, 2022.

With reference to above submission of your idea "Varicose Vein / Hydrogref" to Shivaji Sir/Madam. University Centre for Innovation. Incubation and Linkages (SCIIL) and SUK Research and Development Foundation (SUKRDF), a Section & Company of Shivaji University, Kolhapur under Company Act, 2013 approved by Maharashtra State Innovation Society (MSInS) which is a nodal government agency to boost innovation driven entrepreneurial ecosystem in the state of Maharashtra. MSInS is established under Department of Skill Development and Entrepreneurship, Government of Maharashtra, and aims to foster innovative approaches and create conducive environment for innovative businesses to operate in Maharashtra

With reference to your proposal requesting startup at Incubation Centre of Shivaji University. Kolhapur and consecutive scrutiny by expert committee and approval by authorities, I am directed to inform you that your proposal has been approved and be incubated at Incubation Centre of Shivaji University, Kolhapur. If you join as incubatee, you have to abide by rules and regulations of Shivaji University, SCIIL and SUKRDF.

This is for your information and further necessary action.



Yours sincerely. istopos? Prof. (Dr.) P. b. Raut CEO, SUKRDF

Copy for information to:

1. Registrar, Shivaji University, Kolhapur 2. I/c Director, SCIIL

Signed by: Sidharth Patil Reason: NAAC Location: Kasabe Digraj Date: 29-Jun-2023 (04:58 PM)



CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

	Date: 13/02/2023
To,	
Chief	Executive Officer
SUK R	esearch and Development Foundation,
8-3.5	hivaji University Campus,
Kolhaj	pur-416004
Sub:-/	Acceptance as an Incubatae in SUKRDF
Ref: SUKRE	Your letter dated 13/02/2023 SUK/ SUKRDF/ No. 00217 regarding the offer to be incubatae in F

Sir,

Thank you very much for accepting my idea for incubation in SUKRDF. With reference to your letter, I am accepting your offer to be incubate at the SUK Research and Development Foundation (SUKRDF) from 13/02/2023 My Company name is SKCP Pharma Technologies and the product is Ventone, I will abide by the rules and regulations of SUKRDF.


Thanking you

Yours faithfully,

Name :-Nikhat Samir Maindargi Nikhil Ananda Gajare Cijul Dhanashri Nanaso Mujumale

Company Name: SKCP Pharma Technologies

Signed by: Sidharth Patil Reason: NAAC Location: Kasabe Digraj Date: 29-Jun-2023 (04:58 PM) Sign



CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem


INCUBATION CUM MENTORING AGREEMENT

This Incubation cum Mentoring Agreement ("IMA") is executed at Kolhapur, on this 23 "Day of 14.9~ _20.23

BETWEEN

SUK RESEARCH AND DEVELOPMENT FOUNDATION, an Enterprise of Shivaji University, Kolhapur, under Shivaji University Innovation, Incubation & Linkages (SCIIL) funded by Maharashtra State Innovation Society (MSInS) Government of Maharashtra, dealing within the meaning of and registered under the Companies Act, 1956, a Section 8 Company under the Companies Act 2013, having its Registered Office at B-3, Shivaji University Campus, Shivaji University, Kolhapur - 416004 (hereinafter called 'SUKRDF' which expression shall include its successor-in-interest and permitted assigns) and represented by its Authorized Signatory of the FIRST PART,





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

AND


Shrismt. <u>Nikbal Somir Mainckeri</u> SDW/0 30mir Brizze man an Indian citizen with AADHAR number 852362312041 representing M/s SECP Phartics Testing Dia company registered under the having its registered office at

in the capacity of (Designation birelefter) incubated as a 111100 mode of incubation, hereinafter referred to as "incubatee" which expression shall, include unless repugnant to the context and represented by its Director 11200 Correly Modelefter meaning thereof, mean and include their successors, representatives and permitted assigns) of the SECOND PART.

(SUKRDF and the Incubatee are individually a "Party" and collectively the "Parties".)

Recitals:

- (A) SUKRDF incubates individuals/companies on physical as well as on virtual mode across all sectors with projects/innovative ideas having a potential to develop as sustainable enterprises that provide significant benefits to society in terms of employment generation, contribution to the economy etc. SUKRDF provides incubation support to such entrepreneurs in the nature described in <u>Clause 1.2</u> herein under (Incubation Support).
- (B) The direct goal of SUKRDF incubation support is to enable incubatees to bring their innovative ideas, products and services to the market place.
- (C) The broad objectives of SUKRDF through its Incubation Center include inter-alia: (a) extending assistance to those ideas based on technology, innovative products and services, (b) to augment





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

innovations by providing support for experimentation, scaling up, prototype development, technology or other resources, (c) to link innovators with technological, scientific and managerial experts, (d) to assist innovators through SUKRDF value added services, research, training and other studies, (e) to help in developing capacity of innovators in negotiations, dealing with markets, developing knowledge networks and utilizing market and non-market opportunities and providing management support, (f) promoting new technology based enterprises, commercialization of technologies developed, orientation of entrepreneurs towards business basics/management of business enterprises including help in preparing a business plan, mentoring and consultancy, providing assistance to incubatees in networking with investors, regulatory clearances. IP Management and legal help (g) to encourage, support, assist in the promotion of entrepreneurshipby connecting to state and National Start-up eccosystem, build network of mentors & subject matter experts.

- (D) The Incubatee has applied for incubation support to develop their idea as mentioned in "Business Plan submitted by incubate". The Incubatee is in the stage of experimenting with and developing certain products/services. The Incubatee proposes to set up and develop its product/service and Business with incubation support from SUKRDF, and SUKRDF proposes to provide such incubation support. ("Business")
- (E) The Parties are entering into this IMA to set out the agreed terms and conditions for the provision of incubation support by SUKRDF to the Incubatee.


(F) All annexures to this IMA shall be an integral part of this IMA.

In consideration of the above recitals and the mutual covenants of the Parties, the Parties agree as follows:

1. SUKRDF INCUBATION SUPPORT

- 1.1. <u>Basis for Incubation Support</u>: Based on: (a) the potential of the innovation/idea proposed and the Incubatee to create significant positive social & societal impact, employment and promote entrepreneurship, (b) the commitment of the Incubatee in setting up and developing the Business for creating such impact and reaching such goals, and (c) in furtherance of SUKRDF objects, mandate and core activities as an incubator focused on (i) supporting enterprises that aim to develop innovations in the said sectors, (ii) assisting in setting up and developing the business of such enterprises and achieving growth; SUKRDF will provide Incubation Support to the Incubatee for setting up and growing the Business.
- 1.2. Incubation Support: The incubation support would also include providing technical and business support to the Incubate through providing access to SUKRDF technology data bank, network of partnering National R&D laboratories, institutions, universities and by way of providing unique value added services across the innovation value chain such as technology evaluation, IP Management, Prototype development/field testing, certification, market research, assistance for getting regulatory approvals, preparation of Techno-Economic Feasibility Report, Detailed Project Report and proposals for seeking funding, connecting to Start-up India Mission; connecting the Incubatee with pool of mentors, advisers and subject matter experts as may be relevant; providing







CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

opportunities to connect with investors and others in SUKRDF's networks; other such support as may be relevant for supporting the Incubatee and developing the Business including evaluating the business model (such as to reduce or address challenges and risks). Various incubation support services offered by SUKRDF are attached in **ANNEXURE-A**. There may be consultancy charges for mentoring and advisory services provided by the empanelled mentor/advisory board. The terms of the same would be discussed with the incubatee on a case-to-case basis.

- 1.3. <u>Term</u>: Incubation Support will be provided initially for a period of One <u>(01) year</u> from the date of signing of this IMA ("Term") which can be extended on a mutually agreed for another One (01) year, in no case the term of IMA shall exceed beyond Two (02) years.
- 1.4. <u>Incubatee obligations for receiving Incubation Support</u>: In consideration of receiving Incubation Support and to ensure that such support is provided efficiently by SUKRDF and is received and utilized by the Incubatee in the most beneficial and constructive manner, the Incubatee agrees to:
- (a) Submit a business plan stating the novelty of the technology/idea, business prospects including demand and supply, need for SUKRDF expertise, laboratory and infrastructural requirement for their research and development, commercialization of the technology developed, IPR ownership, financial plan etc.
- (b) Work with SUKRDF to analyse and develop its Business and activities (this includes considering steps for gathering customer insights, determining and refining the value proposition and market fit for the Incubatee's products, services, technologies, innovations or other solutions, developing and refining the business model etc) and
- (c) Restrict activities and operations as per the business plan finally accepted by SUKRDF and to comply with the guidelines, if any; issued by SUKRDF for operations of Incubatee from time to time.
- (d) To furnish information, periodic reports as and when desired by SUKRDF Board. The requisitioned information / reports can be as part of any exercise to monitor/review the progress of incubation in line with the original/revised Business Plan submitted to the institute or to meet requirement of special/contingent/unforeseen circumstance. This also includes any audio-visual presentation requisitioned by SUKRDF.
- (e) Adhere to the activities as mentioned in their application for incubation.
- (f) The Incubatee will work with SUKRDF in a diligent, committed, professional, cooperative and efficient manner. The Incubatee will develop its Business and work on other deliverables that may be identified for the provision of Incubation Support.






CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

- (g) The Incubatee will make efforts in good faith to disseminate information, research and analysis in connection with its Business, Intellectual Property, products, services and innovations. SUKRDF acknowledges and agrees that in the course of undertaking such efforts, the Incubatee may take reasonable precautions in safeguarding against any sensitive information (whether or not this is also Confidential Information) or Intellectual Property relating to the Business becoming available to its competitors.
- (h) The Incubatee will not change or stop the Business, undertake new businesses or activities, take any steps that may adversely affect or reduce the potential impact of the Business, or change its legal form of organization, without prior written approval from SUKRDF.
- (i) If it is determined that the Incubatec's solutions, including the relevant products, services, technologies and innovations, do not have or will not have any considerable impact, or if any change or anticipated change to the Business and activities or form of organization of the Incubatec are reasonably likely to adversely affect or reduce the potential social impact of the Business, then SUKRDF may at its discretion and notwithstanding any other obligations or requirements contained in this IMA, withdraw its Incubation Support and terminate this IMA and upon any Event of Default, exercise its rights under *Clause 5*.
- (j) The Incubatee shall maintain accurate records for the Business and submit such records pertaining to the technical progress of their work every quarter within a month of closure of respective quarter. The Incubatee acknowledges and agrees that this is essential for SUKRDF and the Incubatee to track utilization of the Incubation Support, progress of the Business.
- (k) SUKRDF is entitled to visit the Incubatee's offices (if any) or sites of operation (upon 24 (twenty-four) hours' notice), inspect records (both financial and technical) of the Incubatee (upon 10 working days' notice) and shall have the right to periodic calls or meetings with the Incubatee and procure information as may be required in connection with this IMA.
- 1.5. Consultations:
- (a) The Parties will consult with each other for improving implementation of the IMA, providing assistance and resolving any matters (such as a change in market or business conditions or change in Laws) due to which the IMA may need to be amended or the scope of the Business or deliverables may need to be modified or where any conduct may constitute a breach of Laws.
- (b) The Incubatee represents that it has informed SUKRDF of any discussions with other funders, investors or incubators for fund raising or other support, that were commenced prior to the execution of this IMA. The Incubatee shall: (a) inform SUKRDF prior to any of them commencing any discussions for fund raising from any investor or funder and shall share final drafts of the funding documentation (including term sheets, share purchase or subscription agreements and shareholder agreements) before executing such agreements (so that conflict of interest between SUKRDF and the Incubatee would not arise), and (b) not accept any conditions from a proposed investor or funder that would prevent such information from being shared with SUKRDF.






CRITERION 3: Research, Innovations and Extension


3.2 – Innovation Ecosystem

- 1.6. Incubatec initiative: The Incubatee shall take all necessary initiative and efforts to build and grow the Business. The Incubatee understands that the purpose of SUKRDF Incubation Support is to assist with setting up and development of the early stages of the company and Business and that the Incubatee is expected to take necessary effort to take this forward and continues to grow the company and Business. This includes efforts to build the team, create ESOP plans, create a mentor equity pool and/or other incentives and rewards for mentors and advisors as relevant, develop networks for furthering the Business, meeting governance and compliance requirements, capacity building and all other efforts towards growing the Business.
- 1.7. Financial Support:
- 1.7.1. SUKRDF shall endeavour to connect and demonstrate the Incubatee to the potential angel and Institutional investors and support them in raising funds through the SUKRDF Investor Network orthe outside Investors. The selected Incubatee may be allowed to pitch before the investors on a selected date and venue.
- 1.7.2. As a part of the Incubation Support, SUKRDF may provide financial support to the Incubate for product development/prototyping/field testing/certification etc. from its existing promotional schemes subject to fulfilling the eligibility criteria. However, such financial support is not guaranteed and may be in exchange for equity in the enterprise. The terms and conditions of such an arrangement would be discussed separately, on a case-to-case basis.
- 1.7.3. The Incubatees shall disclose the utilization of funds in advance to the SUKRDF and the funds so raised by the Incubatee shall be used as disclosed.

2. Incubation Costs:

- 2.1. The physical incubatee shall pay to SUKRDF rentals/charges for utilization of the space, utilities, shared facilities, maintenance and incubation services @ Rs.50.00 per Sq. Ft. per month.
- 2.2. The physical Incubatee shall pay an advance rental amount of three (03) months as security deposit and the current month rental charges at the time of signing of this IMA. The physical incubatee shall pay every month the rental charges on or before 7th day of every calendar month. The security deposit would be refunded/adjusted during the exit, considering any deductions, to the space and furniture, excluding general wear and tear.
- 2.3. The virtual Incubatee shall pay an annual membership fees of Rs 20,000/- (Rupees Twenty Five Thousand Only) at the time of signing of this IMA.
- 2.4. In addition to the above fees, SUKRDF shall also charge, on success basis, an amount equivalent to2% (two) of the funds raised by the Incubatee through the connect, contacts, platform and investor network of SUKRDF.
- 2.5. In addition to above fees, the Incubatee shall be obligated to allot/ transfer/issue, free of cost/free of any cash consideration 2% (two) of the promoters' equity at face value on non-dilutable basis to the SUKRDF with a buyback option. The Incubatee shall provide SUKRDF with share certificate duly issued / endorsed in the name or SUKRDF within 1 month from issuance, duly stamped and free from any lien or charge and shall provide adequate proof to the satisfaction of SUKRDF that all







3.2 – Innovation Ecosystem

compliances in respect of such allotment / transfer / issue of 2 % equity shares have been made by the incubatee company as required under the provisions of the Companies Act, 2013 and other applicable provisions of law.

- Incubatee shall, within a month of signing of this IMA, issue 2% (two) of the promoters' equity at face value to SUKRDF.
- 2.7. SUKRDF shall have sole and absolute rights to decide (i) when to offer option of buyback of these equity shares by Incubatec, (ii) quantum thereof, (iii) their valuation and (iv) terms of payment of buyback of equity shares, if any.
- Incubate shall have the option to purchase the Offered Shares or cause the Offered Shares to be purchased from SUKRDF at the above-mentioned price within 30 days from the date of offer for buyback by SUKRDF.
- (II) If Incubatee fails to purchase the Offered Shares or to cause the Offered Shares to be purchased as above, SUKRDF shall be free to treat with the shares in whatever way that suits it without further reference to Incubatee. In such case Incubatee shall be liable to compensate SUKRDF for any shortfall in the amount mentioned above.
- (III) Incubate at all times shall have the First Right to purchase all or part of the Offered Shares that SUKRDF wishes to dispose off.
- All applicable taxes shall be charged extra at actual by the SUKRDF and be solely borne by the Incubatee.
- 2.9. The Incubatee shall be jointly and severally liable for the payment of above costs to the SUKRDF
- 2.10. SUKRDF may change the above rates from time to time at its discretion and date of implementation of the amended charges shall be applicable with immediate effect.
- 2.11. A monthly charge other than office space, will be charged by SUKRDF and shall be payable strictly within seven days from the date of the communication in this regard.
- 2.12. The Incubatee shall have to execute separate agreement for seed money and/or Intellectual Property/know-how, Technology owned by SUKRDF, as and when a request is made and agreed upon by SUKRDF.
- 2.13. The Incubatees shall be jointly and severally liable for the payment of above costs to the SUKRDF.

3. CONFIDENTIALITY

- 3.1. Each Party shall use the same degree of care to safeguard and keep confidential the other Party's Confidential Information as it employs with respect to its own such information.
- 3.2. Not with standing Clause 3.1, each Party may disclose any Confidential Information:






CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

- (a) To its employees, directors, agents and other representatives, its Affiliates, its Affiliates' employees, directors, agents and other representatives, its own professional advisers or those of its Affiliates, subject to such Party requiring that such recipient complies with these confidentiality obligations (each Party shall be responsible to the other for any non-compliance by such employees agents or representatives);
- (b) If required to do so by Law or if requested to do so by any Governmental Authority;
- (c) If and to the extent the other Party has given prior written consent to the disclosure; or
- (d) If otherwise allowed under this IMA, including as described under Clause 3.3 (Dissemination and use of information) hereinunder.
- 3.3. Dissemination and use of information by SUKRDF:
- (a) SUKRDF may use the information received under this IMA relating to the Incubatee and Business for furthering the objects of this IMA and for any analysis or research for its internal use, subject to confidentiality obligations (as mentioned in *Clause 3.1 & 3.2*) of this IMA.
- (b) SUKRDF may share information relating to the Incubatee, Business, Incubation Support under this IMA, with Third Parties such as mentors, advisers, auditors, consultants, lawyers, sector experts, and Governmental Authorities, including for any independent evaluation of such information (such as through a business or legal due diligence). SUKRDF shall request such Third Party recipient to maintain the confidentiality of such information, unless the information being provided is generic in nature (such as basic information on the Incubatee, its activities and impact, status of progress and growth of the Incubatee) ("Generic Information") or is required to be disclosed under applicable Laws or by any Governmental Authority.
- (c) SUKRDF may publicly disclose any Generic Information regarding this IMA, the Incubatee, Business and Incubation Support, including through press releases, public reports, speeches, newsletters and other public communications and documents and on their websites. SUKRDF will consult with the Incubatee if it seeks to publicly disclose information that is deemed to be Confidential Information under this IMA and is not Generic Information, and such information will be made publicly available only upon the prior written consent of the Incubatee.
- (d) Notwithstanding anything contained in this IMA, SUKRDF may disclose any Confidential Information if required to do so by Law or any Governmental Authority. However, to the extent permitted by Law and/or the Governmental Authority, SUKRDF shall: (i) use reasonable efforts to inform the Incubatee of the circumstances for, and the content of, the disclosure at least 48 (fortyeight) hours before making the disclosure, and (ii) consult with the Incubatee on steps to avoid or limit the disclosure if relevant. Provided that the Party required to make the disclosure has taken all reasonable steps to limit, as far as reasonably possible, the extent of such disclosure and has consulted with the other Party before making the disclosure.





CRITERION 3: Research, Innovations and Extension


3.2 – Innovation Ecosystem

4. INDEMNITY

- 4.1. The Incubatee shall indemnify SUKRDF and/or its Affiliates, and the directors, officers, employees, authorized representatives and agents of SUKRDF or its Affiliates ("Indemnified Persons") in respect of any costs, claims, loss or liability suffered by the Indemnified Persons (including reasonable legal costs) as a direct or indirect result of any breach by the Incubatee of the terms (including representations and warmantics) of this IMA or any negligent act or failure to perform (in whole or part) any obligation required to be performed by the Incubatee pursuant to this IMA.
- 4.2. The incubatee hereby agrees to indemnify and save harmless the Indemnified Persons against all losses, liabilities, claims, damages or expenses arising out of legal claims made by third parties relating to the ownership of shares of the company.
- 4.3 The Indemnified person under this clause shall, as soon as practicable after the receipt of written notice ("Indemnify Notice") of the commencement of any claim against such Indemnified person in respect of which indemnity may be sought from the Indemnified person under this clause, notify the Incubate in writing of the commencement thereof.
- (a) Upon such notification, the Incubatee shall assume the defence thereof at its own expense; provided, however, that any Indemnified Person may, at its own expense, retain separate counsel to participate in such defence.
- (b) Notwithstanding the foregoing, in any claim in which both the Incubatee and the Indemnified Person are, or are reasonably likely to become, a party, such Indemnified Person shall have the right to employ separate counsel if, in the reasonable opinion of counsel to such Indemnified Person, either (a) one or more defences are available to the Indemnified Person that are not available to the Incubatee or (b) a conflict or potential conflict exists between the Incubatee and such Indemnified Person that would make such separate representation advisable.

Provided that such other counsel shall act as per the instructions of the Incubatee. The Incubatee shall make all interim payments or deposits that may be required to be made in relation to claim/proceeding/order.

- (c) The Indemnified Person shall promptly notify the Incubatee of a claim at such a time as will enable the Incubatee to participate in the defence of such claim in accordance with this Clause.
- (d) The Incubatee agrees that it will not, without the prior written consent of the Indemnified Person, settle, compromise or consent to the entry of any judgment in any pending or threatened claim relating to the matters contemplated hereby (if any Indemnified Person is a party thereto or has been actually threatened to be made a party thereto) unless such settlement, compromise or consent includes an unconditional release of the Indemnified Person from all liability arising or thatmay arise out of such claim.
- (e) The Indemnified Person shall not be liable for any settlement of any claim affected against an Indemnified Person without its written consent, which consent shall not be unreasonably withheld.





CRITERION 3: Research, Innovations and Extension

3.2 - Innovation Ecosystem

- (f) The rights accorded to an Indemnified Person bereunder shall be in addition to any rights that any Indemnified Person may have under Law or in equity or otherwise; provided, however, that the Indemnified Person shall not make a claim for Losses under this Clause for any claim for which it has already been fully compensated by the Incubatee in pursuance of this Clause or in Law, equity or otherwise.
- The indemnification rights of the Indemnified Persons under this IMA are independent of, and in 4.4 addition to, any other rights and remedies they may have at law or in equity or otherwise, including the right to seek specific performance, rescission or other injunctive relief.
- 4.5 Subject to Applicable Law, the Incubatee agree that under no circumstances shall Indemnified Persons be referred to or otherwise be considered as a "Promoter" (as defined under Companies Act 2013 or otherwise) of the Incubatee including in connection with any Qualified IPO or any documents filed in connection therewith and nor shall they be represented as the promoters to any third party.

EVENTS OF DEFAULT 5.

- Events of default of the Incubatee are: 5.1.
- Material breach of any terms and conditions. (a)
- (b) Delay or failure to achieve the deliverables set out pursuant to this IMA to the reasonable satisfaction of SUKRDF, unless despite the Incubatee having acted in good faith and to the best of its abilities, the failure or delay was due to external factors and challenges such as market, business, regulatory or structural challenges.
- If in the reasonable opinion of SUKRDF there arises any material concern regarding the Incubatee's (c) commitment or ability to work with SUKRDF or develop the Business in the manner set out in this IMA (or otherwise agreed to by the Parties). Instances of such events of default include providing false or misleading information to SUKRDF, failure to engage and work with SUKRDF in a cooperative and constructive manner or a lack of effort, focus or commitment in achieving the milestones.
- (d) Issue of an order, decree or ruling permanently enjoining or prohibiting the Incubatee from performing any obligation or completing any transaction contemplated under this IMA by a courtof competent jurisdiction or any Governmental Authority; or
- Liquidation, dissolution or winding up of the Incubatee. (e)
- Failure to clear any dues including rental and other charges continuously for a period of six (06) (1) months.
- 5.2. Events of default of SUKRDF are any material breach of the terms and conditions of this IMA.





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

6. TERM, TERMINATION & EXIT

- 6.1. The Term of this IMA may be extended or reduced as may be agreed in writing by the Parties.
- 6.2. The IMA can be terminated at any time as may be agreed upon by the Parties in writing.
- 6.3. SUKRDF shall have the right to terminate this IMA upon the purpose of Incubation Support being achieved or where Incubation Support is no longer relevant or required for the Incubatee. This includes situations where the Incubatee has achieved all relevant deliverables or has raised funding from other sources or has demonstrated adequate growth such that Incubation Support is no longer relevant.
- 6.4. If either Party ("Defaulting Party") defaults under this IMA under any of the events of default described in *Clause 5* (Events of Default) and has not rectified the default within 7 (seven) days (or such other period as may be agreed between the Parties) of receiving a written notice from the other Party ("Non-Defaulting Party"), the Non-Defaulting Party is entitled to terminate the IMA. It is clarified that there is no obligation on the Non-Defaulting Party to terminate this IMA upon a default by the Defaulting Party.
- 6.5. Termination of this IMA will not relieve any Party of any obligation or liability accrued before termination.
- 6.6. The exercise of any right by a Party, including termination of the IMA pursuant to an event of default, shall be without waiver or prejudice to any other right, remedy, power or privilege available to the Party under the IMA or Law or to any other or further exercise of the right.

7. GOVERNING LAW AND DISPUTE RESOLUTION

A

(i) If any dispute or difference arises between the parties hereto as to the construction, interpretation, effect and implication of any provision of this IMA including the rights or liabilities or any claim or demand of any claim or demand of any party against other or in regard to anyother matter under these presents but excluding any matters, decisions or determination of which is expressly provided for in this IMA, such disputes or differences shall be settled under the Rules of Kolhapur International Arbitration Centre, Kolhapur by Sole Arbitrator to be appointed out of the Panel of Arbitrators of Kolhapur International Arbitration Centre, Kolhapur by Sole Arbitrator to the consent of both the parties failing which the aggrieved party shall approach to the Court of competent jurisdiction for appointment of Sole Arbitrator in accordance with the Arbitration & Conciliation Act, 1996 (as amended/modified from time to time) and rules framed thereunder for the time being in force(the ACT) and the reference to arbitration shall be deemed to be submission within the meaning of the ACT.

(ii) If however, the Incubatee does not make any claim or demand or raise any dispute or difference in terms of this clause within one year from the date on which such claim or demand arises, the Incubatee shall be deemed to have waived and abandoned such claim or demand or theright to raise such dispute or difference against SUKRDF.

(iii) (a) The venue of the arbitration shall be at Kolhapur International Arbitration Centre at Kolhapur





CRITERION 3: Research, Innovations and Extension

3.2 – Innovation Ecosystem

(b) Each party shall bear and pay its own cost of the arbitration proceedings unless the Arbitrator otherwise decides in the Award.


(c) The provisions of this Clause shall not be frustrated, abrogated or become inoperative notwithstanding this IMA expires or ceases to exist or is terminated or revoked or declared unlawful.

8 The High Court of Mumbai at Mumbai and Courts subordinate to it shall have exclusive jurisdiction in all matters concerning this IMA including any matter arising out of the arbitration proceedings or any Award made therein.

8. MISCELLANEOUS

- <u>Assignment</u>: Except for SUKRDF, this IMA may not be assigned by either Party without the prior written consent of the other Party.
- Expenses: Each Party will bear and pay its respective costs and expenses (including professional fees and costs of its advisors and counsel).
- 8.3. <u>Waiver</u>: The failure of a Party to insist upon strict performance of any provision of this IMA or to exercise any right or remedy to which it is entitled, will not constitute a waiver.
- 8.4. <u>Good faith</u>: Each Party will act in good faith in interpreting and implementing this IMA and will do or procure to be done all things reasonably within its power which is necessary or desirable to give effect to the provisions and spirit and intent of this IMA.
- 8.5. <u>Reliance on judgment and advice</u>: Each Party acknowledges that it has entered into this IMA relying on its own business judgment and advice of its own advisers. Each of SUKRDF and the Incubatee and/or its promoters represents and acknowledges that it has not been induced by the other Party to enter into this IMA.
- Amendment: Any amendment to this IMA shall be mutually agreed in writing and executed by the Parties.
- 8.7. <u>Severability</u>: If any provision of this IMA is held invalid, illegal or unenforceable for any reason by any court of competent jurisdiction, such provision will be severable and the remaining provisions will continue in full force and effect as if this IMA had been executed with the invalid provision eliminated.
- 8.8. Force majeure: No Party shall be responsible for any failure to comply with this IMA (other than the failure to pay or delay in paying amounts due, which shall not be subject to this sub-clause), or for any delay in performance of, or failure to perform under, this IMA where such failure or delay is due to acts and circumstances which are beyond the control of such Party, which shall include: acts of God such as fire, storm, flood, earthquake, explosion or accident; acts of war or terrorism or civil unrest; failures or delays in transportation; strikes; acts of any government, whether national, municipal or otherwise, or any agency thereof. In such event, the non-performing Party is excused from further performance for as long as such circumstances prevail and the Party







3.2 – Innovation Ecosystem


continues to use its reasonable endeavors to recommence performance. Any Party so delayed shall promptly notify the other and describe the circumstances causing the delay.

- 8.9. <u>No Third Party Beneficiaries</u>: Unless otherwise specified, this IMA is solely for the benefit of the Parties and no provision of this IMA shall be deemed to confer upon Third Parties any remedy, claim, liability, reimbursement and claim of action or other right in excess of those existing without reference to this IMA.
- 8.10. <u>Standing Advisory Committee(SAC)</u>: Standing Advisory Committee constituted by the competent authority shall guide the incubation team in selecting the suitable incubatee and review theprogress of the incubation centre time to time and provide all the necessary direction and strategic vision for growth of incubation centre.
- - .
- 8.11. Notices: Notices will be given by the Parties in the manner described as under.
 - a. All notices and other communications required to be served on the SUKRDF including for violation of the terms of this IMA shall be considered to be duly served if the same shall have been delivered by registered mail at its address as below:

Chief Executive Officer, SUK Research & Development Foundation, B-3, Shivaji University Campus, Kolhapur-416004 Maharashtra.

- b. Similarly, any notice to be given to the Incubate shall be considered as duly served if the same shall have been delivered by registered mail at its address as below:
- 8.12. No agency or partnership: This IMA is entered into on a principal to principal basis. Nothing in this IMA shall constitute a partnership or joint venture between the Parties under applicable Indian laws or constitute either Party as the agent, partner or principal of the other. Neither Party shall beentitled to contract in the name of or on behalf of the other or otherwise to incur obligations for oron behalf of the other unless specifically authorized in writing to do so.
- 8.13. <u>Disclaimer</u>: SUKRDF shall provide Incubation Support in good faith and with reasonable efforts. SUKRDF does not make any representation or warranty with respect to the Incubation Support provided under this IMA and there is no guarantee that Incubation Support will achieve the desired results for the Incubatee; ensuring quality of support by SUKRDF to the complete satisfaction of the residentcompany/incubatee & the quality of the services of the consultants engaged by the resident company/incubatee through SUKRDF networks. SUKRDF will not be liable for any acts or omissions in the performance of this IMA except if such acts or omissions are due to the wilful misconduct or gross negligence of SUKRDF. The incubatee/resident company agrees that SUKRDF or their employees shall not be held liable for any reason on account of the above.







CRITERION 3: Research, Innovations and Extension 3.2 – Innovation Ecosystem

9. This IMA shall become effective on and from the date it is signed.

IN WITNESS WHEREOF, both the parties herein set their respective hands and seals on the day.month and year first above written in the presence of following witnesses.

For and on behalf of

For and on behalf of Incubatee

CEO, SUKRDF

SUK Research and Development Foundation

Nikhat S. Maindarg, Nikhil A. Sujare

Double to Ingunale

Witness 1. Signature 94 Name: br. sanfash Eyope

Address: Ap-Taigash Address: Ap-Taigash Address: Ap-Taigash Address: Ap-Taigash Address: Address Addre

Address:

Witness

Name:

1. Signature :

2. Signature

Name:

Address:

2. Signature :

Name :

Address :

